Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM225CWN | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 13.3 | uM | 7534.091 | 0.6538 | 0.3018 | 0.9898 | |
| SUM225CWN | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 66.7 | uM | 7534.091 | 0.4550 | -0.0973 | 0.9898 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 0.0000853 | uM | 7535.092 | 0.9168 | 0.8515 | 1.1267 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 0.000427 | uM | 7535.092 | 0.8977 | 0.8174 | 1.1267 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 0.00213 | uM | 7535.092 | 0.9900 | 0.9823 | 1.1267 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 0.0107 | uM | 7535.092 | 0.9431 | 0.8987 | 1.1267 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 0.0533 | uM | 7535.092 | 0.8975 | 0.8169 | 1.1267 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 0.267 | uM | 7535.092 | 0.8641 | 0.7569 | 1.1267 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 1.33 | uM | 7535.092 | 0.8518 | 0.7346 | 1.1267 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 6.67 | uM | 7535.092 | 0.7673 | 0.5810 | 1.1267 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 33.3 | uM | 7535.092 | 0.5103 | 0.1007 | 1.1267 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7536.09 | 0.8741 | 0.7746 | 1.1257 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7536.09 | 0.8772 | 0.7802 | 1.1257 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7536.09 | 0.9364 | 0.8867 | 1.1257 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7536.09 | 0.7663 | 0.5789 | 1.1257 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 0.107 | uM | 7536.09 | 0.9096 | 0.8385 | 1.1257 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 0.533 | uM | 7536.09 | 0.8008 | 0.6418 | 1.1257 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 2.67 | uM | 7536.09 | 0.9092 | 0.8378 | 1.1257 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 13.3 | uM | 7536.09 | 0.7000 | 0.4569 | 1.1257 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 66.7 | uM | 7536.09 | 0.6996 | 0.4561 | 1.1257 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7537.091 | 1.0025 | 1.0024 | 2.0227 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7537.091 | 0.9245 | 0.9238 | 2.0227 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7537.091 | 0.9796 | 0.9798 | 2.0227 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7537.091 | 0.9810 | 0.9811 | 2.0227 | |
| SUM229PE | TNBC | - | Erlotinib | EGFR | ErbB | 0.107 | uM | 7537.091 | 0.8893 | 0.8873 | 2.0227 |